Research programme: antiviral therapeutics - Ennaid Therapeutics

Drug Profile

Research programme: antiviral therapeutics - Ennaid Therapeutics

Latest Information Update: 17 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ennaid Therapeutics
  • Class Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chikungunya virus infections; Dengue; West Nile virus infections; Zika virus infection

Most Recent Events

  • 16 Feb 2016 Preclinical trials in Chikungunya virus infections, Dengue, West Nile virus infection, and Zika virus infection in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top